Alternatively, early tau seeds, while sharing some qualitative properties with late-stage AD seeds, might represent biochemically and/or structurally distinct tau forms generated independently of pathogenic outcomes, and we cannot rule out the possibility that they occur regularly in normal individuals. The gene discussed is MAPT; the disease is Alzheimer disease.